Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis (Sclerocadh1)

Grenoble Alpes University Hospital Center (CHU)

Status: Completed

Conditions: Systemic Sclerosis; Primary Raynaud Disease

Treatments: Biological: soluble Ve cadherin

Study type: Interventional

Funder types: Other

Identifiers

NCT02212249

2014-A00186-41

Details and patient eligibility

About

Ve-cadherin is expressed in endothelial cells. Systemic slerosis is a rare auto-immune disease with a endothelial dysfunction. This study is to evaluated the level of soluble VE-cadherin and VE-cadherin antibody in patients with systemic slerosis.

Enrollment: 85 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• group 1: systemic sclerosis
• group 2: raynaud primary disease

Trial design

85 participants in 2 patient groups

Systemic sclerosis

Active Comparator group

Description:

patients with systemic sclerosis

Treatment:

Biological: soluble Ve cadherin

primary raynaud disease

Sham Comparator group

Description:

patients with primary raynaud disease

Treatment:

Biological: soluble Ve cadherin